5 completed. 5 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 1 | 1 | Completed 1 |
Follow plitidepsin: new trials by email Literature Review of plitidepsin trials Research Report on plitidepsin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) Plitidepsin 1.5 mg/day, Placebo, Placebo and Plitidepsin 1.5mg/day - Post COVID-19 Condition, Long COVID Syndrome | Phase 2 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 90 | 2025-02-07 | 2026-10-08 |
| Extension Study in a Cohort of Adult Patients With COVID-19 Infection Plitidepsin 1.5 mg / day, Plitidepsin 2.0 mg / day, Plitidepsin 2.5 mg / day - COVID-19 Infection | Phase 1 / Phase 2 | Completed | PharmaMar | 34 | 2022-01-25 | 2024-12-31 |
| Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis APLIDIN (plitidepsin) - Myelofibrosis | Phase 2 | Completed | PharmaMar | 12 | 2010-07-01 | 2020-10-12 |
| A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma Plitidepsin - Multiple Myeloma | Phase 2 | Completed | PharmaMar | 51 | 2005-02-01 | 2009-12-24 |
| Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Aplidin® - Leukemia, Lymphoma | Phase 2 | Completed | PharmaMar | 67 | 2004-12-01 | 2018-04-25 |
COVID-19 (2) · Leukemia (1) · Lymphoma (1) · Multiple Myeloma (1) · Neoplasms, Plasma Cell (1) · Post-Acute COVID-19 Syndrome (1) · Primary Myelofibrosis (1)
PharmaMar (4) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1)
Spain (3) · Italy (2) · United States (2) · France (1) · Peru (1) · Puerto Rico (1) · Switzerland (1)
Pablo Guisado-Vasco, MD (1) · Paul Richardson, MD (1) · Pedro Landete, MD (1) · Roger Paredes, MD (1) · Vincent Ribrag, MD (1)